Recombinant humanized monoclonal antibody MIL93(Mabworks)
重组人源化单克隆抗体MIL93（天广实）
Report date: 2025/02/12 09:48:42
Base Information
Drug NameRecombinant humanized monoclonal antibody MIL93(Mabworks)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[5]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Mabworks Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesBeijing Mabworks Biotech Co Ltd
Inactive CompaniesN/A
Active Indications +[4]
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A